0000899243-19-017092.txt : 20190614 0000899243-19-017092.hdr.sgml : 20190614 20190614181353 ACCESSION NUMBER: 0000899243-19-017092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190612 FILED AS OF DATE: 20190614 DATE AS OF CHANGE: 20190614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Scott A. CENTRAL INDEX KEY: 0001703394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 19900044 MAIL ADDRESS: STREET 1: C/O CYTODYN INC. STREET 2: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-12 0 0001175680 CytoDyn Inc. CYDY 0001703394 Kelly Scott A. 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 1 0 0 0 Common Stock 2019-06-12 4 M 0 50000 0.40 A 1293170 D Common Stock 2019-06-12 4 A 0 25000 A 1318170 D Common Stock 691208 I By Spouse Common Stock 23180 I As Custodian for Daughter; See Footnote Common Stock 22980 I As Custodian for Daughter; See Footnote Warrant (Right to Buy) 1.35 2019-06-12 4 D 0 50000 D 2016-05-26 2021-05-26 Common Stock 50000 0 D Warrant (Right to Buy) 0.40 2019-06-12 4 A 0 50000 A 2016-05-26 2021-05-26 Common Stock 50000 50000 D Warrant (Right to Buy) 0.40 2019-06-12 4 M 0 50000 0.00 D 2016-05-26 2021-05-26 Common Stock 50000 0 D On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants. Dr. Kelly disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. /s/ Michael D. Mulholland, as attorney-in-fact 2019-06-14